



The original disclosure in Japanese was released on Oct. 21, 2021 at 15:30 (GMT+9)

To whom it may concern,

Company name:	Takara Holdings Inc.
Company representative:	Mutsumi Kimura, President
Securities code and stock exchange listings:	2531 Tokyo (1st section)
Inquiries:	Masakazu Usami, General Manager of Financial & Investor Relations Dept.
Company name:	Takara Holdings Inc.
TEL:	(075)241-5124

### Revision of Consolidated Business Results Forecast for the First Half of the Fiscal Year Ending March 31, 2022

Kyoto, Japan—Takara Holdings announced revisions to the business results forecast for the first half of the fiscal year ending March 31, 2022 (from April 1, 2021, to March 31, 2022) that it released on August 3, 2021, as stated below. These revisions were based on consideration of recent performance trends.

1. Revised figures for the business results forecast for the first half of the fiscal year ending March 31, 2022 (from April 1, 2021, to September 30, 2021)

(Millions of yen / %)

	Net sales	Operating income	Ordinary income	Net income attributable to owners of the parent	Net income per share
Previous forecast (A) (August 3, 2021, announcement)	140,000	18,100	18,200	7,800	39.45yen
Revised forecast (B)	141,213	21,616	21,884	10,050	50.84yen
Change (B—A)	1,213	3,516	3,684	2,250	—
Change (%)	0.9	19.4	20.2	28.8	—
Reference: Previous business results (First half of the fiscal year ended March 31, 2021)	127,784	5,782	5,940	2,761	13.97yen

## 2. Reason for revision

For the first half of the fiscal year ending March 31, 2022, overall consolidated net sales are expected to exceed the previous forecast (announced on August 3, 2021) with higher net sales for the Takara Bio Group, although net sales for Takara Shuzo are projected to be lower than the forecast.

In terms of profit, operating income, ordinary income, and net income attributable to owners of the parent are expected to exceed the previous forecast, with higher gross profit due to the increase in net sales and a decrease in the cost of sales ratio.

For the six months ended September 30, 2021, net sales and all profit items are projected to be at all-time highs.

The performance by each business segment is as follows.

### [Takara Shuzo]

In Japan, the market for products for commercial use has slumped as a result of the prolonged state of emergency due to COVID-19, and products such as sake and shochu in particular have faced harsh conditions. In addition, with regard to light-alcohol refreshers, the impact of the voluntary product recall implemented in the first quarter has extended through the second quarter, and overall net sales for the first half of the fiscal year ending March 31, 2022 are expected to be lower than the previous forecast.

Operating income is expected to exceed the previous forecast, as a result of efforts to generate profits through thorough cost reduction.

### [Takara Shuzo International Group]

In overseas markets, net sales for the first half of the fiscal year ending March 31, 2022 are expected to slightly exceed the previous forecast, due to a strong performance in exports from Japan, in addition to a recovery in the eating and drinking establishment market and the expansion of sales channels to retailers and online sales, among others.

Operating income is expected to exceed the previous forecast, as a result of holding down SG&A expenses, in addition to an increase in net sales.

### [Takara Bio Group]

In the Biomedical Business, net sales are expected to exceed the previous forecast for general research reagents, which are continuing to recover from the impact of COVID-19, and PCR testing-related products for COVID-19.

Operating income is expected to exceed the previous forecast, with an anticipated increase in the profit margin due to factors such as an increase in net sales and an improvement in the cost of sales ratio for contract services.

Further, today consolidated subsidiary Takara Bio Inc. (The First Section of Tokyo Stock Exchange, security code number: 4974) also announced revisions to forecasts for the six-month period ended September 30, 2021

## 3. Full-year business results forecast for the fiscal year ending March 31, 2022

The Company is currently evaluating whether or not revisions to forecasts for consolidated business results for the full fiscal year are necessary and considering the details of possible revisions. The Company will make an announcement in this regard when it announces its business results for the first half on November 9, 2021.

\* The above-mentioned forecasts have been prepared based on the information available as of the date of announcement of this document and could differ from the business result figures scheduled to be announced on November 9, 2021.

---

### Cautionary Statement on the Use of This Document

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.